A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

Recruiting now · Phase 1

Conditions studied: High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC)

In brief

The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.

Key facts

Study ID

NCT06476808

Run by

Bristol-Myers Squibb

People needed

240

Starts

2024-09-06

Expected to finish

2028-12-19

Last updated by the study team

2026-07-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
• Participants must have at least 1 lesion accessible for biopsy in addition to the target lesion, from which a fresh pre treatment biopsy must be obtained.
• Participants must have an unresectable/metastatic carcinoma.

You may not qualify if…

• Participants must not have Leptomeningeal metastases.
• Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment.
• Participants must not have had any prior radiation therapy within 2 weeks prior to start of study treatment.
• Other protocol-defined Inclusion/Exclusion criteria apply.

Where it is running

• USC/Norris Comprehensive Cancer Center — Los Angeles, California, United States (enrolling)
• Valkyrie Clinical Trials — Los Angeles, California, United States (enrolling)
• John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey, United States (enrolling)
• BC Cancer Vancouver — Vancouver, British Columbia, Canada (enrolling)
• Princess Margaret Cancer Centre — Toronto, Ontario, Canada (enrolling)
• Centre Hospitalier de l'Université de Montréal — Montreal, Quebec, Canada (enrolling)
• Jewish General Hospital — Montreal, Quebec, Canada (enrolling)
• Local Institution - 0032 — Milan, Italy
• Local Institution - 0042 — Barcelona, Barcelona [Barcelona], Spain
• Local Institution - 0041 — Avda.Pio XII 36,, Spain
• Local Institution - 0036 — Bordeaux, Aquitaine, France
• Local Institution - 0031 — Villejuif, Val-de-Marne, France
• Local Institution - 0035 — Lyon, France
• Local Institution - 0045 — Columbus, Ohio, United States
• Local Institution - 0046 — Dallas, Texas, United States
• Local Institution - 0049 — Houston, Texas, United States
• Local Institution - 0033 — Milan, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.